title: [One-year therapy with dihydroergocristine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study].
abstract: This double-blind study of dihydroergocristine (DHEC, CAS 17479-19-5) versus placebo was performed in 240 elderly patients affected by chronic cerebrovascular disease or organic brain syndrome. The therapy was carried on for one year. Results pointed out a decrease of SCAG total score and a significant improvement of the target items "confusion, mental alertness and memory performance" after DHEC versus placebo. Furthermore the data show that DHEC maintained its activity throughout the 12-month trial period. Very few and mild side-effects were reported for both groups, thus confirming the well known good safety of the compound. Based on results of this 1-year investigation, it is concluded that DHEC treatment should not be abruptly interrupted, but continued for as long as possible.
authors: Abteilung für Innere Medizin, Krankenhaus von Vaprio, d'Adda, Mailand, Italien.
authors: G
authors: G
authors: Agliati
authors: M
authors: M
authors: Lazzaroni
authors: G
authors: G
authors: Mariani
authors: F
authors: F
authors: Marras
authors: N
authors: N
authors: Massetto
authors: C
authors: C
authors: Menozzi
authors: E
authors: E
authors: Ortenzi
authors: G
authors: G
authors: Perna
authors: N
authors: N
authors: Puppo
authors: S
authors: S
authors: Santambrogio
mesh_terms: D000368:Aged; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000523:psychology; D008875:Middle Aged
chemical_list: D004088:Dihydroergotoxine
vernacular_title: Einjährige Therapie mit Dihydroergocristin zur Behandlung von Aufmerksamkeits- und Gedächtnisstörungen bei älteren Patienten. Plazebo-kontrollierte multizentrische Studie.